 "Dr Reddy's up 4% after receiving EIR from USFDA for Srikakulam Unit I")
Dr Reddy’s Laboratories has moved higher by 4% to Rs 2,409 on BSE in intra-day trade after the company received an Establishment Inspection Report (EIR) from the US health regulator for a unit of its Srikakulam plant in Andhra Pradesh.
“The company's formulation Srikakulam plant (SEZ) Unit I, Andhra Pradesh, have received an Establishment Inspection Report (EIR) from the US FDA,” Dr Reddy’s Laboratories said in BSE filing.
On June 16, 2017, the pharmaceutical company had said the USFDA issued a Form 483 with one observation on completion of audit of the above-referred facility.
Last week, Dr Reddy’s said that it had received EIR from the USFDA for a unit II of its Srikakulam plant in Andhra Pradesh. It, however, did not state if the US health regulator had made any observation in the EIR.
In a separate filing the company said it had received zero observations for its custom pharmaceutical services facility, technology development centre, at Miyapur in Hyderabad after audit of the facility by the USFDA.
In past one month, the stock has outperformed the market by surging 17% as compared to 2% decline in the S&P BSE Sensex.
“The company's formulation Srikakulam plant (SEZ) Unit I, Andhra Pradesh, have received an Establishment Inspection Report (EIR) from the US FDA,” Dr Reddy’s Laboratories said in BSE filing.
On June 16, 2017, the pharmaceutical company had said the USFDA issued a Form 483 with one observation on completion of audit of the above-referred facility.
Last week, Dr Reddy’s said that it had received EIR from the USFDA for a unit II of its Srikakulam plant in Andhra Pradesh. It, however, did not state if the US health regulator had made any observation in the EIR.
In a separate filing the company said it had received zero observations for its custom pharmaceutical services facility, technology development centre, at Miyapur in Hyderabad after audit of the facility by the USFDA.
In past one month, the stock has outperformed the market by surging 17% as compared to 2% decline in the S&P BSE Sensex.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%